The long-term goal of our proposal is to elucidate the molecular mechanisms by which protein tyrosine phosphatase T (PTPRT) functions as a tumor suppressor. In a high-throughput mutational analysis, we identified PTPRT as the most frequently mutated phosphatase in human colon cancers. Recent exome sequencing studies uncovered that PTPRT is also mutated in lung, gastric, and ovarian cancers, in head &neck squamous cell carcinomas, and in melanomas. In the previous funding period, we demonstrated that Ptprt knockout (KO) mice are prone to develop colon cancer, thereby providing critical in vivo evidence to support the premise that PTPRT functions as a tumor suppressor. Using a cutting-edge phospho-proteomic approach, we identified STAT3 and paxillin as PTPRT substrates. PTPRT dephosphorylates the key STAT3 activation site Y705. Our preliminary studies showed that, compared to wild-type littermates, intestinal stem cells in Ptprt KO mice are more proliferative and that pY705 STAT3 is up-regulated in the intestinal stem cell compartments of Ptprt KO mice. In light of recent exciting studies by others demonstrating that intestinal stem cells are the origin of intestinal tumors, we will determine in Aim 1 how PTPRT regulates intestinal stem cell homeostasis and whether PTPRT-regulated STAT3 signaling plays a critical role in intestinal stem cell homeostasis and the in vivo tumor suppressor function of PTPRT. In addition, PTPRT dephosphorylates a previously unstudied paxillin phospho-tyrosine site, Y88 (pY88). We found that pY88 paxillin is up-regulated in a majority of human colon cancer specimens. Interestingly, our preliminary studies showed that very high levels of pY88 paxillin associate with advanced-stage colon cancers, suggesting that pY88 paxillin may be exploited as a prognostic biomarker. Moreover, we engineered paxillin Y88F mutant knock-in colon cancer cell lines and demonstrated that they exhibit reduced tumor formation in vitro and fail to form xenograft tumors in nude mice. Together, our studies suggest that pY88 paxillin mediates pivotal oncogenic signaling in colon cancer.
In Aim 2, we will focus on elucidating the mechanisms by which pY88 paxillin signaling promotes oncogenesis.
In Aim 3, we will determine if the PTPRT-regulated pY88 paxillin pathway can be exploited as a prognostic marker for colon cancer. Success in these studies will result in delineation of novel mechanisms underlying intestinal stem cell homeostasis and colon tumorigenesis, provide a novel prognostic tool to guide clinical management of this deadly disease, and define a potentially important new therapeutic target. Because PTPRT is mutated in multiple human cancers, knowledge gained from these studies may have broad implications for cancer therapy.

Public Health Relevance

Colorectal cancer is the second most common cause of cancer deaths in the United States, with 150,000 new cases and 55,000 deaths per year. Advances in understanding the molecular pathogenesis of this disease are fundamental to our understanding of cancer development and successful clinical intervention. Our proposed studies will delineate novel mechanisms underlying colon cancer development, define novel therapeutic targets, and search for new prognostic tool to guide clinical management of this deadly disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Molecular Oncogenesis Study Section (MONC)
Program Officer
Yassin, Rihab R,
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
Schools of Medicine
United States
Zip Code
Lui, Vivian Wai Yan; Peyser, Noah D; Ng, Patrick Kwok-Shing et al. (2014) Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A 111:1114-9
Koon, Henry B; Krown, Susan E; Lee, Jeannette Y et al. (2014) Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042. J Clin Oncol 32:402-8
Hao, Yujun; Zhao, Shuliang; Wang, Zhenghe (2014) Targeting the protein-protein interaction between IRS1 and mutant p110* for cancer therapy. Toxicol Pathol 42:140-7
Scott, Anthony; Song, Jing; Ewing, Rob et al. (2014) Regulation of protein stability of DNA methyltransferase 1 by post-translational modifications. Acta Biochim Biophys Sin (Shanghai) 46:199-203
Feng, Xiujing; Scott, Anthony; Wang, Yong et al. (2014) PTPRT regulates high-fat diet-induced obesity and insulin resistance. PLoS One 9:e100783
Liu, Bo; Cong, Rixin; Peng, Bin et al. (2014) CtIP is required for DNA damage-dependent induction of P21. Cell Cycle 13:90-5
Song, J; Wang, Z; Ewing, R M (2014) Integrated analysis of the Wnt responsive proteome in human cells reveals diverse and cell-type specific networks. Mol Biosyst 10:45-53
Hao, Yujun; Wang, Chao; Cao, Bo et al. (2013) Gain of interaction with IRS1 by p110*-helical domain mutants is crucial for their oncogenic functions. Cancer Cell 23:583-93
Guan, D; Factor, D; Liu, Yu et al. (2013) The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein. Oncogene 32:3819-28
Zhang, P; Guo, A; Possemato, A et al. (2013) Identification and functional characterization of p130Cas as a substrate of protein tyrosine phosphatase nonreceptor 14. Oncogene 32:2087-95

Showing the most recent 10 out of 20 publications